CTOs on the Move

Meiogen Biotechnology Corporation

www.meiogen.com

 
Meiogen Biotechnology Corporation is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.meiogen.com
  • 100 Cummings Ctr Ste 431a
    Beverly, MA USA 01915
  • Phone: 978.927.0878

Executives

Name Title Contact Details

Similar Companies

BioSkryb

Bioskryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.

Ansun Biopharm

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. Paradase is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.

CinCor Pharma

CinCor is a clinical-stage biopharmaceutical company targeting cardiovascular, metabolic and kidney diseases.

Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel`s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.

Response Genetics

Response Genetics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.